Pain Management

Many times, unfortunately, the root cause of a dependence upon or abuse of opioids by those suffering from the crisis that is crippling our nation is pain.  Pain is a debilitating problem with enormous individual and societal costs. Pain affects more Americans than heart disease, diabetes and cancer combined, and is the most common reason American access the health care system as well as the number one cause of disability. According to the National Institutes of Health (NIH), roughly 25 million suffer from chronic pain. Recent studies have found that chronic pain and opioid misuse together cost the U.S. economy more than $1 trillion annually.   

To aid in efforts to address the opioid crisis, MDMA has established a pain management working group. This working group is tasked with identifying therapies that could serve as an alternative to opioids to treat pain as well as barriers to patient access and greater adoption by payers and providers. FDA Commissioner Dr. Scott Gottlieb has stated before Congress that the agency has approved nearly 200 different medical devices that have components to treat chronic and acute pain. A report from the President's Commission on Combating Drug Addiction and the Opioid Crisis identified "medical technology devices" as having a role to play in efforts to combat the crisis. 

Congress and policy makers are working to address this crisis, and we know that medical technology innovation can play a critical role in this important work. This working group meets meet periodically via teleconference to share ideas and shape policies to facilitate greater adoption of medical technology solutions to help in the opioids crisis. Participants also receive timely and relevant email distributions with breaking and/or news announcements. We encourage you or your team to join this working group. If you and your team would like to join the MDMA Pain Management working group, please email Meredith Taylor at

Click here to view the President's Commission on Combating Drug Addiction and the Opioid Crisis

Click here to view MDMA's comments to the Finance Committee


Latest News

MDMA Statement on Senate Passage of the “Opioid Crisis Response Act of 2018”

Washington, D.C. – Mark Leahey, President and CEO of MDMA, issued the following statement regarding Senate passage of the “Opioid Crisis Response Act of 2018...